第 1 到 3 筆結果,共 3 筆。
公開日期 | 題名 | 作者 | 關聯 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2019 | Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer. | Han, Y; Li, CW ; Hsu, JM; Hsu, JL; Chan, LC; Tan, X; He, GJ | American journal of cancer research 9(4), 800-815 | |||
2 | 2019 | Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. | Han, Y; Chen, MK; Wang, HL; Hsu, JL; Li, CW ; Chu, YY; Liu, CX; Nie, L; Chan, LC; Yam, C; Wang, SC; He, GJ; Hortobagyi, GN; Tan, XD; Hung, MC | American journal of cancer research 9(3), 608-618 | |||
3 | 2019 | Palmitoylation stabilizes PD-L1 to promote breast tumor growth. | Yang, Y; Hsu, JM; Sun, L; Chan, LC; Li, CW ; Hsu, JL; Wei, Y; Xia, W; Hou, J; Qiu, Y; Hung, MC | Cell research 29(1), 83-86 |